Literature DB >> 3033966

Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone.

B Allolio, H M Schulte, U Deuss, D Kallabis, E Hamel, W Winkelman.   

Abstract

To further investigate the role of opioids in the regulation of the pituitary-adrenal axis we studied the effect of morphine and naloxone on human corticotropin-releasing hormone (hCRH)-induced ACTH, immunoreactive (ir) beta-endorphin, and cortisol release in normal subjects. Protocols: 1. 30 mg of a slow-release preparation of morphine or placebo was given orally 3 h prior to administration of hCRH (0.1 mg iv) (N = 7). 2. Naloxone (4 mg as bolus iv) or placebo was given 5 min prior to hCRH (N = 7). 3. Naloxone (4 mg iv as bolus followed by a continuous infusion of 6 mg over 75 min) or placebo was started 15 min prior to hCRH (N = 6). hCRH was injected at 11.00 h (protocol 1, 2) or at 17.00 h (protocol 3). Oral morphine not only suppressed basal hormone levels (P less than 0.02), but also the peak response to hCRH compared with placebo (cortisol: 270 +/- 50 vs 559 +/- 80 nmol/l; ACTH: 5.1 +/- 1.5 vs 13.1 +/- 2.7 pmol/l; ir beta-endorphin: 48.5 +/- 8.7 vs 88 +/- 14 pmol/l; mean +/- SEM, P less than 0.02). Similarly, the maximum incremental changes and the area under the curve were significantly reduced for all three hormones compared with placebo (P less than 0.05). After 4 mg of naloxone in the morning, no significant hormonal changes in response to hCRH were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033966     DOI: 10.1530/acta.0.1140509

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  21 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 2.  Making a bad thing worse: adverse effects of stress on drug addiction.

Authors:  Jessica N Cleck; Julie A Blendy
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 3.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  Serum cortisol secretion during heroin abstinence is elevated only nocturnally.

Authors:  Su-xia Li; Jing Li; David H Epstein; Xiang Yang Zhang; Thomas R Kosten; Lin Lu
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

5.  Tramadol-induced adrenal insufficiency.

Authors:  Miguel Debono; Sharon Chan; Christen Rolfe; T Hugh Jones
Journal:  Eur J Clin Pharmacol       Date:  2011-01-18       Impact factor: 2.953

Review 6.  Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids.

Authors:  Renato Vellucci; Consalvo Mattia; Ludovica Celidonio; Rocco Domenico Mediati
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

7.  Serotonin transporter-linked polymorphic region (5-HTTLPR) genotype is associated with cortisol responsivity to naloxone challenge.

Authors:  Mary Ann C Stephens; Mary E McCaul; Elise M Weerts; Gary Wand
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

Review 8.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

9.  Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary-adrenal axis in rhesus monkeys.

Authors:  Jillian H Broadbear; Gail Winger; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2004-04-28       Impact factor: 4.530

10.  Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.

Authors:  G P Bernini; G F Argenio; F Cerri; F Franchi
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.